PDT Partners LLC Purchases New Holdings in McKesson Corporation $MCK

PDT Partners LLC bought a new position in shares of McKesson Corporation (NYSE:MCK) during the 2nd quarter, HoldingsChannel reports. The fund bought 22,100 shares of the company’s stock, valued at approximately $16,699,000. McKesson accounts for approximately 0.9% of PDT Partners LLC’s holdings, making the stock its 14th largest holding.

A number of other hedge funds also recently modified their holdings of MCK. University of Texas Texas AM Investment Management Co. bought a new position in McKesson in the 4th quarter valued at about $25,000. Swiss RE Ltd. acquired a new position in shares of McKesson in the 4th quarter valued at approximately $26,000. State of Wyoming bought a new stake in shares of McKesson during the 2nd quarter worth approximately $29,000. Kingdom Financial Group LLC. bought a new stake in shares of McKesson during the 4th quarter worth approximately $33,000. Finally, Birchwood Financial Partners Inc. acquired a new stake in shares of McKesson during the 4th quarter worth approximately $33,000. Institutional investors own 85.07% of the company’s stock.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson agreed to acquire Precision Medicine Group for approximately $2.25 billion. The transaction would add clinical research, consulting and biopharma commercialization capabilities to McKesson’s oncology-focused business, broadening its exposure to higher-growth healthcare services. Reuters article about McKesson’s Precision Medicine acquisition
• Positive Sentiment: McKesson raised its fiscal 2027 earnings outlook as oncology demand, GLP-1 volumes and specialty pharmaceutical distribution accelerate. The higher guidance reinforces expectations for double-digit earnings growth and supports investor confidence in the company’s growth strategy. McKesson FY2027 guidance article
• Positive Sentiment: Short interest fell 33% to about 2.42 million shares as of August 14, representing roughly 2.1% of shares outstanding and 2.2 days of average trading volume. The decline suggests reduced bearish positioning and may provide additional support for the stock.
• Neutral Sentiment: Healthcare stocks broadly advanced late Tuesday, giving McKesson a favorable sector backdrop. However, sector-wide gains do not necessarily reflect company-specific fundamentals. Healthcare sector update
• Negative Sentiment: Analysts caution that McKesson’s premium valuation leaves less room for execution setbacks. Drug-pricing pressure, potential policy changes and cash-flow demands associated with expansion and acquisitions remain risks to the investment thesis. McKesson valuation analysis

McKesson Stock Up 3.5%

Shares of NYSE:MCK opened at $904.31 on Wednesday. The firm has a market cap of $105.43 billion, a P/E ratio of 24.20, a P/E/G ratio of 1.72 and a beta of 0.30. McKesson Corporation has a 12-month low of $673.38 and a 12-month high of $999.00. The business has a fifty day simple moving average of $825.22 and a 200 day simple moving average of $844.60.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. The company had revenue of $105.38 billion for the quarter, compared to the consensus estimate of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The firm’s revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, equities research analysts expect that McKesson Corporation will post 44.65 EPS for the current year.

McKesson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Tuesday, September 1st will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. This is a boost from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date of this dividend is Tuesday, September 1st. McKesson’s payout ratio is 8.78%.

Insider Transactions at McKesson

In other news, EVP Thomas L. Rodgers sold 699 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $735.27, for a total transaction of $513,953.73. Following the completion of the sale, the executive vice president owned 2,268 shares in the company, valued at $1,667,592.36. The trade was a 23.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley E. Lerman sold 301 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 23,111 shares of company stock worth $18,011,274. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on MCK shares. Evercore reiterated an “outperform” rating on shares of McKesson in a research note on Thursday, August 6th. William Blair assumed coverage on McKesson in a research report on Tuesday, April 28th. They set an “outperform” rating for the company. UBS Group raised their price objective on McKesson from $1,050.00 to $1,080.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Citigroup lifted their target price on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Finally, Barclays boosted their target price on McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $973.44.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.